EW vs. ISRG, ZBH, ALGN, DXCM, COR, IQV, TAK, MRNA, CNC, and IDXX
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Intuitive Surgical (ISRG), Zimmer Biomet (ZBH), Align Technology (ALGN), DexCom (DXCM), Cencora (COR), IQVIA (IQV), Takeda Pharmaceutical (TAK), Moderna (MRNA), Centene (CNC), and IDEXX Laboratories (IDXX). These companies are all part of the "medical" sector.
Intuitive Surgical (NASDAQ:ISRG) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
Edwards Lifesciences received 292 more outperform votes than Intuitive Surgical when rated by MarketBeat users. Likewise, 71.77% of users gave Edwards Lifesciences an outperform vote while only 69.05% of users gave Intuitive Surgical an outperform vote.
In the previous week, Edwards Lifesciences had 16 more articles in the media than Intuitive Surgical. MarketBeat recorded 42 mentions for Edwards Lifesciences and 26 mentions for Intuitive Surgical. Edwards Lifesciences' average media sentiment score of 0.70 beat Intuitive Surgical's score of 0.55 indicating that Intuitive Surgical is being referred to more favorably in the media.
83.6% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 0.9% of Intuitive Surgical shares are owned by insiders. Comparatively, 1.3% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Intuitive Surgical currently has a consensus price target of $396.17, suggesting a potential upside of 5.55%. Edwards Lifesciences has a consensus price target of $92.71, suggesting a potential upside of 7.27%. Given Intuitive Surgical's higher probable upside, analysts clearly believe Edwards Lifesciences is more favorable than Intuitive Surgical.
Intuitive Surgical has a net margin of 27.16% compared to Intuitive Surgical's net margin of 23.01%. Intuitive Surgical's return on equity of 23.34% beat Edwards Lifesciences' return on equity.
Intuitive Surgical has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.
Summary
Intuitive Surgical beats Edwards Lifesciences on 11 of the 18 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
